Lotus Pharmaceutical Co., Ltd. · TWSE:1795
Lotus Pharmaceutical — Investor Presentation (April 2020)
17 slides from Lotus Pharmaceutical's investor presentation, April 2020
Slide 1: Lotus Pharmaceuticals Investor Presentation April 2020
LOTUS PHARMACEUTICALS Investor presentation 1795.TT APRIL 2020
Slide 2: Safe Harbor Statement
Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and Safe uncertainties that could cause actual results to differ materially. These forward looking statements are not based on historical facts but
Slide 3: Today's Agenda
Today’s Agenda 1 Recent Operational Updates 2 Strategic Tactics Towards 2020
Slide 4: Recent Operational Highlights
RECENT OPERATIONAL HIGHLIGHTS
Slide 5: Successful Transition to Become a Global Contender
SUCCESSFUL TRANSITION TO BECOME A GLOBAL CONTENDER › Strong year delivered with 43% top line growth, driven by successful execution of export portfolio › Buprenorphine/Naloxone sublingual film as 1st wave generics in the US › 1st to market of 3 leading oncology products in EU › Significant strategic
Slide 6: Fruitful Year in 2019 with Remarkable Achievements
FRUITFUL YEAR IN 2019 WITH REMARKABLE ACHIEVEMENTS FINANCIAL RESULTS Strong revenue growth Key Financials Revenue driven by successful YoY expansion of export (in NTD Millions, except EPS) 2018 2019 +43% % portfolio Net Sales 6,429 9,175 43% Cost of Goods 3,289 4,927 Gross profit 3,139 4,248 35% OP
Slide 7: Q1'20 Sales Update
Q1’20 SALES UPDATE Q1 Sales Breakdown NT$2,183mn NT$1,964mn ~30% ~20% +2% if excluding gSuboxone sales ~80% ~70% Q1'19 Q1'20 Asian market NCS Other Export gSuboxone 7
Slide 8: Continue to Capitalize on Successful Launches
CONTINUE TO CAPITALIZE ON SUCCESSFUL LAUNCHES Buprenorphine/Naloxone Market Dynamics Qsymia Launching Progress • Bup/Nal market share has ramped up as expected Qsymia has taken leadership position in prescription number within 6th weeks after launch 25% 25% Weekly UBIST data, within new generation p
Slide 9: Strategic Tactics Towards 2020
STRATEGIC TACTICS TOWARDS 2020
Slide 10: We Are Well-Positioned to Achieve Sustainable Growth
WE ARE WELL-POSITIONED TO ACHIEVE SUSTAINABLE GROWTH Well-established STRATEGIC TACTICS FOR EXECUTION foundation with To fuel future growth successful transition Solid Two-pronged Expansion Strategy Backed By in 2020 & beyond 1 in 2019… Well-covered footprints in Asia as home base Strong Global Comm
Slide 11: Well-Covered Infrastructure in APAC Region to Capture Growth Opportunities
WELL-COVERED INFRASTRUCTURE IN APAC REGION TO CAPTURE GROWTH OPPORTUNITIES Korea Taiwan • 12 sales office • 3 sales office • 225 S&M forces covering General • 104 S&M forces covering Medical Hospitals, Hospitals, and Clinics Centers, Hospitals, General Practices, national-wide and Pharmacies nationa
Slide 12: Strong Partnership with Industry Leaders to Expand Addressable Markets Globally
STRONG PARTNERSHIP WITH INDUSTRY LEADERS TO EXPAND ADDRESSABLE MARKETS GLOBALLY 110+ licensing deals are signed to cover more than 130 Global Partners markets – all Lotus self-developed products Gefitinib Vinorelbine Ulipristal Temozolomide NORTH 9 AMERICA Lenalidomide Enzalutamide Sunitinib LATAM 2
Slide 13: Unparalleled R&D Capabilities with Continuous Investment in Portfolio
UNPARALLELED R&D CAPABILITIES WITH CONTINUOUS INVESTMENT IN PORTFOLIO Strategic Focus Talent Pool Ongoing Projects ▪ Strategic focus on oral oncology 10+ on going Largest number of scientists Oncology Lenalidomide, Enzalutamide, etc. products for the global (US/EU/Japan) among peers: 2251 markets, l
Slide 14: Major R&D Pipeline Update
MAJORE R&D PIPELINE UPDATE Focus on high value innovation for patients and customers KEY ONCOLOGY PROJECT IQVIA market size Generic Name Indication Formulation BE & CT Submission Approval ‘19 (US$mn) GDUFA 1 Lenalidomide Multiple Myeloma Global: 10,000 Out-licensing scope continues to expand Settled
Slide 15: Major R&D Pipeline Update (Cont'd)
MAJORE R&D PIPELINE UPDATE (CONT’D) Focus on high value innovation for patients and customers N0N-ONCOLOGY PROJECT IQVIA market size Generic Name Indication Formulation BE & CT Submission Approval ‘19 (US$mn) Treatment for moderately to 1 LP117 severely active rheumatoid Global: 1,432 arthritis (RA)
Slide 16: Site Master Plan & Upgrade to Ensure Quality Manufacturing
SITE MASTER PLAN & UPGRADE TO ENSURE QUALITY MANUFACTURING 2019 2020 2021 2022 New warehouse Area C Upgrade & High Containment QC Extension/ Upgrade Site Upgrade projects 16
Slide 17: Major Catalysts to Watch in FY2020
MAJOR CATELYSTS TO WATCH IN FY2020 Expansion of brand portfolio in Asian markets GDUFA TAD in Jul’20 for Lenalidomide Development of ASEAN markets, including TH, VN, DX market Qsymia launch Solid sales stream backed by successful export portfolio expansion (Bup/Nal + key oncology products) in 2019 w
Lotus Pharmaceutical — Investor Presentation (April 2020) on 6ix